• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Economics of Indication-Based Drug Pricing.

作者信息

Chandra Amitabh, Garthwaite Craig

机构信息

From the Harvard Kennedy School, Cambridge, MA (A.C.); and the Kellogg School of Management, Northwestern University, Evanston, IL (C.G.).

出版信息

N Engl J Med. 2017 Jul 13;377(2):103-106. doi: 10.1056/NEJMp1705035.

DOI:10.1056/NEJMp1705035
PMID:28700848
Abstract
摘要

相似文献

1
The Economics of Indication-Based Drug Pricing.基于适应症的药品定价经济学
N Engl J Med. 2017 Jul 13;377(2):103-106. doi: 10.1056/NEJMp1705035.
2
Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.针对不合理的处方药价格——马里兰州的反价格欺诈法。
N Engl J Med. 2017 Jul 13;377(2):101-103. doi: 10.1056/NEJMp1704907. Epub 2017 Jun 7.
3
Value-Based Pricing and Patient Access for Specialty Drugs.专科药物的价值定价与患者可及性
JAMA. 2018 Jun 5;319(21):2169-2170. doi: 10.1001/jama.2018.5367.
4
Prescription-drug coupons--no such thing as a free lunch.处方药优惠券——天下没有免费的午餐。
N Engl J Med. 2013 Sep 26;369(13):1188-9. doi: 10.1056/NEJMp1301993. Epub 2013 Aug 28.
5
Value-Based Pricing for Drugs: Theme and Variations.基于价值的药品定价：主题与变奏
JAMA. 2018 Jun 5;319(21):2165-2166. doi: 10.1001/jama.2018.4871.
6
Pharmaceuticals and Medical Devices: Cost Savings.药品和医疗器械：成本节约。
Issue Brief Health Policy Track Serv. 2017 Dec 26;2017:1-31.
7
Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.昂贵的药物：药品价格越来越让人难以承受。有效的治疗方法却难以寻觅。
Minn Med. 2017 May;100(3):10-17.
8
Analysis of State-Level Drug Pricing Transparency Laws in the United States.美国州级药品定价透明度法律分析。
JAMA Netw Open. 2019 Sep 4;2(9):e1912104. doi: 10.1001/jamanetworkopen.2019.12104.
9
Rebates-The Little-Known Factor Behind Increasing Drug List Prices.回扣——药品目录价格上涨背后鲜为人知的因素。
JAMA. 2020 Mar 3;323(9):812-813. doi: 10.1001/jama.2020.1208.
10
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.一项不完整的药方：特朗普总统解决高药价问题的计划。
JAMA. 2018 Jun 19;319(23):2373-2374. doi: 10.1001/jama.2018.7424.

引用本文的文献

1
Assessment of Financial Impact of Expanding the Scope of Drug Usage in South Korea.韩国扩大药品使用范围的财务影响评估。
Int J Health Policy Manag. 2025;14:8812. doi: 10.34172/ijhpm.8812. Epub 2025 Jul 13.
2
What Can Economics Say about Alzheimer's Disease?经济学对阿尔茨海默病能有何见解？
J Econ Lit. 2023 Jun;61(2):428-470. doi: 10.1257/jel.20211660.
3
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers.欧洲罕见癌症政策评估：医疗服务提供者调查
Cancers (Basel). 2025 Jan 7;17(2):164. doi: 10.3390/cancers17020164.
4
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.基于价值的特定适应症定价和加权平均定价：癌症药物的估计价格和成本节省
Pharmacoeconomics. 2025 Apr;43(4):415-427. doi: 10.1007/s40273-024-01448-x. Epub 2024 Dec 30.
5
Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs.及时、廉价还是无风险？监管对新药价格和可及性的影响。
Pharmacy (Basel). 2024 Mar 18;12(2):50. doi: 10.3390/pharmacy12020050.
6
Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination.事前监管投资：来自药品专利审查的证据。
Am Econ J Econ Policy. 2023 Aug;15(3):151-183. doi: 10.1257/pol.20200703.
7
Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries.医疗保健支付方对肿瘤多适应症产品评估与定价的观点：来自九个经合组织国家的证据
Pharmacoecon Open. 2023 Jul;7(4):553-565. doi: 10.1007/s41669-023-00406-1. Epub 2023 Mar 23.
8
Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries.多治疗适应症药品的上市序贯：来自七个国家的证据。
BMC Health Serv Res. 2023 Feb 13;23(1):150. doi: 10.1186/s12913-023-09095-2.
9
Trastuzumab deruxtecan chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis.曲妥珠单抗德鲁昔单抗治疗HER2低表达晚期乳腺癌患者：一项基于美国的成本效益分析。
Front Pharmacol. 2022 Oct 28;13:1025243. doi: 10.3389/fphar.2022.1025243. eCollection 2022.
10
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.美国、德国、法国、英国、加拿大、澳大利亚和苏格兰的多适应症癌症药物的价值和价格。
Appl Health Econ Health Policy. 2022 Sep;20(5):757-768. doi: 10.1007/s40258-022-00737-w. Epub 2022 Jul 11.